# OnCo record talazoparib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/talazoparib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "talazoparib" ;
  schema:name "Talazoparib"@en ;
  schema:description "Talazoparib is a PARP inhibitor that traps PARP on DNA about 100 times more strongly than olaparib, which is why it works at a 1 mg daily dose. It is approved for germline BRCA-mutant HER2-negative breast cancer and, with enzalutamide, for HRR-mutant castration-resistant prostate cancer; anaemia is its dominant side effect."@en ;
  schema:url <https://onco.cc/drugs/talazoparib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Talazoparib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q25100990> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talazoparib>, <https://www.nice.org.uk/guidance/ta952>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TALZENNA%22>, <https://www.nice.org.uk/guidance/ta1130> ;
  onco:status "approved" ;
  onco:modality "Small-molecule PARP inhibitor" ;
  schema:alternateName "Talzenna" ;
  onco:approval "US 2018: gBRCA HER2- locally advanced/metastatic breast cancer", "US 2023: HRR-mutant mCRPC with enzalutamide", "EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer (EMBRACA); marketing authorisation issued 20 June 2019", "UK 2024: HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after an anthracycline or a taxane; NICE TA952 (21 February 2024) recommends within the marketing authorisation with a commercial arrangement" ;
  onco:related <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/nct04821622/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/> .